Released May 9, 2023, before the open
10-Q filed May 9, 2023, 39 days after period end · 0001576885-23-000025
Q1 2023 · 10-Q
Revenue—
Net Income-$11.31M-$11.31M N/M vs Q1 2022N/M vs Q4 2022
EPS Diluted-$0.28-$0.28 N/M vs Q1 2022no prior Q4 2022 on file
Operating Income-$13,135,000N/M
Operating Cash Flow-$10,175,000N/M
Free Cash Flowderived-$10,175,000N/M
What the release said
The release
Same quarter
| Metric | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|
| Net Income | -$11.31M | -$9.13M | -$27.00M |
| EPS Diluted | -$0.28 | -$0.23 | -$64.41 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acumen Pharmaceuticals, Inc. · CIK 1576885 · Engraved from SEC EDGAR